L1CAM and neuroblastoma: Children suffering from primary refractory or relapsed neuroblastoma were treated with L1CAM-targeting CAR T cells in an ongoing clinical phase I trial (NCT02311621, https: clinicaltrials.gov, accessed on 27 September 2021).